Losartan Recalled Expanded: Ten Lots Recalled
On January 3, 2019, the FDA issued yet another recall of Losartan Potassium tablets. The first recall was issued November 9, 2018 and involved 2 lots. Now, Torrent Pharmaceuticals Limited is recalling a total of 10 lots due to the unexpected impurity N-nitrosodiethylamine (NDEA) found in the drug.
Losartan is a medication used to treat hypertension. It was recalled following the recall of similar drugs Valsartan and Irbesartan for containing NDEA and N-nitrosodimethylamine (NDMA). These substances are classified as probable human carcinogens by the Environmental Protection Agency. Exposure to NDEA can cause:
- Liver cancer
- Pancreatic cancer
- Stomach cancer
- Colon cancer
- Bladder cancer
- Kidney cancer
The products subject to recall can be found on the FDA’s website, which lists the product description, batch/lot number, and expiration date.
If you or a loved one was diagnosed with liver, kidney, pancreatic, stomach, colon, or bladder cancer after taking Losartan, please contact us. We have over 30 years of experience handling dangerous drug cases. At GoldenbergLaw, we deliver the Gold standard advocacy you deserve.